Virtual biotech company puts thousands of AI scientist agents to work
4 hours ago
- Stanford Medicine has launched a virtual biotech company with 37,000 AI agents, led by James Zou and Harrison Zhang, to simulate the entire drug development pipeline.
- The AI agents analyzed 50,000 clinical trials in under a week, identifying that drugs targeting switch-like genes with high bimodality and cell specificity are 40-48% more likely to succeed and have fewer adverse events.
- The virtual biotech designed an antibody-drug conjugate for the B7-H3 protein in lung cancer, which was later independently validated by a pharmaceutical company and received FDA breakthrough therapy designation.
- Zou plans to test the virtual biotech's new findings in real labs, emphasizing that human experimentation remains essential for translating AI discoveries into practical treatments.